Xilio Therapeutics (XLO)CFO sold ~$4.5K

~$4.5K

Approx. value · 7,030 sh @ $0.6432

25K

Holds after · shares reported

Traded

Jan 2, 2026

Filed

Jan 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
2. Nov 21, 2025Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the special meeting of stockholders of Xilio Therapeutics, Inc. (the “Company”) held on November 21, 2025 (the “Special Meeting”), the Company’s stockholders approved the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the “2025 Plan”), which had previously been adopted by the Company’s Board of Directors subject to stockholder approval.”
3. Jan 2, 2026 · this disclosureInsiderCFO sold ~$4.5K of XLO shares in the open market

What came next

1. Jan 2, 2026InsiderOfficer sold ~$1.2K of XLO shares in the open market
2. Jan 6, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On January 8, 2026, the Company announced the appointment of Sara M. Bonstein as chair of the Board. Ms. Bonstein succeeds Paul Clancy, who notified the Company of his decision to retire from the Board on January 6, 2026, effective as of such date.”
3. Feb 11, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
4. Mar 12, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year
5. Mar 23, 2026Company filing · Form 8-K · ResultsReported its results
6. Mar 26, 2026InsiderDirector purchased ~$44K of XLO shares in the open market
7. Apr 15, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 15, 2026, the Board of Directors (the "Board") of Xilio Therapeutics, Inc. (the "Company"), on the recommendation of the Nominating and Corporate Governance committee of the Board, elected Cheryl R. Blanchard, Ph.D., as a Class III director of the Company, with a term expiring at the Company's 2027 annual meeting of stockholders, to serve until her successor has duly been elected and qualified or until her…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Xilio Therapeutics

OQRO holds no insider, Congress, fund or contract record for Xilio Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XLO page.

Other recent filings by Christopher James Frankenfield, Chief Financial Officer

• SEC Form 4 at Xilio Therapeutics (XLO)Jan 3, 2025

The full history of Christopher James Frankenfield, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Xilio Therapeutics

• SEC Form 4Mar 30, 2026
• SEC Form 4Jan 5, 2026
• SEC Form 4Jun 18, 2025
• SEC Form 4Jun 18, 2025
• SEC Form 4Jun 18, 2025
• SEC Form 4Jan 3, 2025

Everything OQRO holds on this company is on its XLO page.